Related Experiment Video
Updated: Aug 18, 2026
Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells
Published on: July 29, 2016
Inhibition of myogenesis in mouse C2 cells by double-stranded phosphorothioate oligodeoxynucleotides containing mef-1
1Department of Molecular Biology and Genetics, University of Guelph, Guelph, Ontario N1G 2W1, Canada.
Abstract:
Phosphorothioate oligonucleotides containing the muscle creatinine kinase enhancer sequence (mef-1) and a mutant of the enhancer sequence (mmef-1) were tested for their ability to block muscle differentiation in mouse C2 cells in culture. Maximum inhibition of fusion of myoblasts was observed at 10 microM concentration of mef-1 oligomer. No appreciable inhibition of fusion with the mmef-1 oligomer at the same concentration was observed. Synthesis of myogenin, muscle creatinine kinase, and myosin heavy chain polypeptides were reduced in mef-1 oligomer-treated cells. In contrast, no significant reduction in the synthesis of these polypeptides in mmef-1-treated cells was detected. The overall protein synthesis was not affected. These results suggest that muscle differentiation may be disrupted by competition of the oligomer with the endogenous promoter for specific transcription factor(s).
Insights
Phosphorothioate oligonucleotides targeting the muscle creatinine kinase enhancer (mef-1) effectively blocked muscle cell differentiation and key protein synthesis in mouse C2 cells. A mutant sequence (mmef-1) showed no significant inhibitory effects.
Area of Science:
- Molecular Biology
- Cell Biology
- Biochemistry
Background:
- Muscle differentiation is a complex process regulated by specific transcription factors and enhancer elements.
- Understanding the molecular mechanisms controlling myogenesis is crucial for regenerative medicine and disease research.
Purpose of the Study:
- To investigate the inhibitory effects of phosphorothioate oligonucleotides targeting the muscle creatinine kinase enhancer (mef-1) on muscle differentiation in mouse C2 cells.
- To determine if a mutant enhancer sequence (mmef-1) could also inhibit this process.
Main Methods:
- Treatment of mouse C2 myoblasts with mef-1 and mmef-1 phosphorothioate oligonucleotides at varying concentrations.
- Assessment of myoblast fusion inhibition.
- Analysis of the synthesis of muscle-specific proteins, including myogenin, muscle creatinine kinase, and myosin heavy chain, using techniques like Western blotting or immunoprecipitation.
- Evaluation of overall protein synthesis to ensure specificity of the observed effects.
Main Results:
- Maximum inhibition of myoblast fusion was achieved at 10 microM concentration of the mef-1 oligomer.
- The mmef-1 oligomer did not significantly inhibit myoblast fusion at the same concentration.
- Treatment with mef-1 oligomer led to reduced synthesis of myogenin, muscle creatinine kinase, and myosin heavy chain polypeptides.
- No significant reduction in the synthesis of these muscle-specific proteins was observed in cells treated with the mmef-1 oligomer.
- Overall protein synthesis remained unaffected, indicating a specific disruption of differentiation pathways.
Conclusions:
- Phosphorothioate oligonucleotides targeting the mef-1 enhancer can effectively block muscle differentiation.
- The inhibitory effect is sequence-specific, as the mmef-1 mutant did not produce similar results.
- These findings suggest that targeting specific enhancer elements with antisense oligonucleotides is a viable strategy to disrupt muscle differentiation, potentially by interfering with transcription factor binding.
